RefleXion Names Dr. Shervin ‘Sean’ Shirvani as Chief Medical Officer

December 4, 2020

HAYWARD, Calif., Dec. 4, 2020 – RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) as a new modality for treating all stages of cancer, today announced the promotion of Shervin ‘Sean’ Shirvani, M.D., MPH, to chief medical officer (CMO) effective immediately.

Dr. Shirvani joined RefleXion in July 2018 as vice president of medical affairs and was promoted to senior vice president of clinical and medical affairs in August 2019. Before joining RefleXion, Dr. Shirvani served as a faculty radiation oncologist and medical director at MD Anderson Cancer Center’s Arizona affiliate. He previously served as a physician leader for Banner Medical Group, where he oversaw operations for multiple specialties, including medical oncology.

“Since joining RefleXion, I have been impressed and inspired by Sean’s clear vision for our technology and his unwavering commitment to advancing cancer care through a rigorous clinical program,” said Todd Powell, RefleXion’s president and CEO. “His diverse oncology background, operational experience and medical expertise make Sean the ideal person to shape and drive our clinical potential. I am thrilled to have him fill this enormously important role for RefleXion.”

“I joined RefleXion because I was inspired by the fountainhead of opportunities for clinical development and product offerings that I believe will improve the lives of countless late-stage cancer patients,” said Dr. Shirvani, CMO for RefleXion. “I firmly believe that BgRT holds exceptional promise for changing the tone of the millions of late-stage cancer discussions that occur every year in oncology clinics across the globe.”

Dr. Shirvani is a board-certified licensed physician from Duke University. He completed dual residencies in Internal Medicine at Stanford University Medical Center and Radiation Oncology at MD Anderson Cancer Center. Dr. Shirvani received a Master’s in Public Health from the University of Texas, Houston. He has authored numerous publications, national practice guidelines, and book chapters on stereotactic radiotherapy and healthcare economics.

About RefleXion Medical

RefleXion is a privately-held therapeutic oncology company developing the first biology-guided radiotherapy (BgRT) machine, with the potential to move beyond single tumor therapy to one day treat multiple metastatic tumors throughout the body in the same treatment session. Currently, the RefleXion X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with sub-second latency.

*The RefleXion™ X1 is cleared for SBRT/SRS/IMRT treatments. BgRT is limited by U.S. law to Investigational use.

Media Contact

Amy Cook